Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE

February 07, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm

Topics Lawsuit

February 03, 2023

From Bragar Eagel & Squire

Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.

Analyst Ratings for Fate Therapeutics ↗

January 24, 2023

Via Benzinga

February 02, 2023

From Robbins LLP

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics, Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023

February 01, 2023

From Kirby McInerney LLP

ROSEN, A TOP RANKED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

February 01, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Fate Therapeutics, Inc. (NASDAQ: FATE) Investor Notice: Lawsuit Alleges Securities Laws Violations ↗

Topics Lawsuit

January 31, 2023

San Diego, CA -- (SBWIRE) -- 01/31/2023 -- An investor, who purchased NASDAQ: FATE shares, filed a lawsuit against Fate Therapeutics, Inc over alleged violations of Federal Securities Laws.

Via SBWire

NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE

January 30, 2023

From Robbins Geller Rudman & Dowd LLP

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm

January 29, 2023

From Bragar Eagel & Squire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

January 29, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Topics Lawsuit

5 Cheapest Health Care Stocks You Should Think About ↗

January 27, 2023

Via Benzinga

ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

January 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

Topics Lawsuit

January 26, 2023

From Glancy Prongay & Murray LLP

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

January 25, 2023

From Law Offices of Howard G. Smith

INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE

January 25, 2023

From Robbins Geller Rudman & Dowd LLP

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Via MarketBeat

Topics Workforce

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)

January 24, 2023

From Robbins LLP

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 24, 2023

From The Law Offices of Frank R. Cruz

Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate

January 24, 2023

From Bronstein, Gewirtz & Grossman, LLC

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

January 24, 2023

From The Schall Law Firm

FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm

January 23, 2023

From Bragar Eagel & Squire, P.C.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Glancy Prongay & Murray LLP

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Kirby McInerney LLP

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Law Offices of Howard G. Smith

Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline

January 23, 2023

From Lowey Dannenberg, P.C.

EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE

January 23, 2023

From The Rosen Law Firm, P.A.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

January 23, 2023

From The Schall Law Firm

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 19, 2023

From Glancy Prongay & Murray LLP